Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Palovarotene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG known ✓ | P13631 | 12/20 | 0.57 |
| ▸ | RARB | P10826 | 12/20 | 0.57 |
| ▸ | RARA | P10276 | 11/20 | 0.57 |
| ▸ | RXRA | P19793 | 13/20 | 0.48 |
| ▸ | RXRB | P28702 | 4/20 | 0.48 |
| ▸ | RXRG | P48443 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palovarotene SCHEMBL4658931 | 1.00 | RARB (0.57) | RARBRARGRARARXRARXRB | |
| Palovarotene SCHEMBL29354070 | 1.00 | RARB (0.57) | RARBRARGRARARXRARXRB | |
| SCHEMBL14159842 | 0.92 | RARB (0.47) | RARBRARGRARARXRARXRB | |
| SCHEMBL14159856 | 0.91 | RARA (0.46) | RARBRARGRARARXRARXRB | |
| SCHEMBL4666458 | 0.90 | RARB (0.55) | RARBRARGRARARXRARXRB | |
| SCHEMBL4666453 | 0.90 | RARB (0.55) | RARBRARGRARARXRARXRB | |
| SCHEMBL14159839 | 0.90 | RARB (0.44) | RARBRARGRARARXRARXRB | |
| SCHEMBL4666954 | 0.90 | RARA (0.44) | RARBRARGRARARXRARXRB | |
| SCHEMBL17635784 | 0.90 | RARA (0.44) | RARBRARGRARARXRARXRB | |
| SCHEMBL4710933 | 0.89 | RARA (0.45) | RARBRARGRARARXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124176-A1 | INHIBITOR FOR RETINOCHOROIDAL DISORDERS | UNIV YAMAGUCHI (JP) | 2026-05-07 | — | — | US | claimed |
| US-12357613-B2 | Inhibitor for retinochoroidal disorders | YAMAGUCHI UNIVERSITY (JP) | 2025-07-15 | — | — | US | claimed |
| US-20250108022-A1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | THOMAS JEFFERSON UNIVERSITY | 2025-04-03 | — | — | US | claimed |
| EP-3446690-B1 | INHIBITOR FOR RETINOCHOROIDAL DISORDERS | UNIV YAMAGUCHI (JP) | 2024-09-11 | — | — | EP | claimed |
| US-12023312-B2 | Composition and method for muscle repair and regeneration | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-02 | — | — | US | claimed |
| US-20240180873-A1 | INHIBITOR FOR RETINOCHOROIDAL DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2024-06-06 | — | — | US | claimed |
| EP-4066826-B1 | RETINOIC ACID RECEPTOR GAMMA AGONISTS FOR MUSCLE REPAIR AND REGENERATION | UNIV JEFFERSON (US) | 2024-03-06 | — | — | EP | claimed |
| US-20240000768-A1 | METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH SULFATASE DEFICIENCIES | GEORG AUGUST UNIV GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS UNIVS (DE) | 2024-01-04 | — | — | US | claimed |
| US-11730718-B2 | Inhibitor for retinochoroidal disorders | YAMAGUCHI UNIVERSITY (JP) | 2023-08-22 | — | — | US | claimed |
| US-20230255937-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2023-08-17 | — | — | US | claimed |
| US-20170065562-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2017-03-09 | — | — | US | claimed |
| US-9492431-B2 | Therapeutic agent for keratoconjunctive disorders | YAMAGUCHI UNIVERSITY (JP) | 2016-11-15 | — | — | US | claimed |
| US-20160120843-A1 | INHIBITOR FOR RETINOCHOROIDAL DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2016-05-05 | — | — | US | claimed |
| US-9314439-B2 | Composition and method for muscle repair and regeneration | THOMAS JEFFERSON UNIVERSITY (US) | 2016-04-19 | — | — | US | claimed |
| EP-3000466-A1 | INHIBITOR FOR RETINOCHOROIDAL DISORDERS | Yamaguchi University (JP) | 2016-03-30 | — | — | EP | claimed |
| US-20150290172-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2015-10-15 | — | — | US | claimed |
| EP-2918290-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | Yamaguchi University (JP) | 2015-09-16 | — | — | EP | claimed |
| US-20140363402-A1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | THOMAS JEFFERSON UNIVERSITY (US) | 2014-12-11 | — | — | US | claimed |
| US-20140303223-A1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | THOMAS JEFFERSON UNIVERSITY | 2014-10-09 | — | — | US | claimed |
| CN-103200937-A | Compositions and methods for muscle repair and regeneration | UNIV JEFFERSON | 2013-07-10 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730718-B2 | Inhibitor for retinochoroidal disorders | ALDH1A2, MMP1, RBP1 | RARG 14/4885RARB 11/4885RARA 21/4885 |
| US-20150290172-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | RARG, RARB, RARA | RARG 1/4885RARB 2/4885RARA 3/4885 |
| US-20240180873-A1 | INHIBITOR FOR RETINOCHOROIDAL DISORDERS | ALDH1A2, MMP1, RBP1 | RARG 14/4885RARB 11/4885RARA 21/4885 |
| US-20260124176-A1 | INHIBITOR FOR RETINOCHOROIDAL DISORDERS | ALDH1A2, MMP1, COL1A1 | RARG 51/4885RARB 26/4885RARA 87/4885 |
| US-20230255937-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | RARG, RARB, RARA | RARG 1/4885RARB 2/4885RARA 3/4885 |
| US-20170065562-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | RARG, RARB, RARA | RARG 1/4885RARB 2/4885RARA 3/4885 |
| US-20160120843-A1 | INHIBITOR FOR RETINOCHOROIDAL DISORDERS | ALDH1A2, MMP1, RBP1 | RARG 14/4885RARB 11/4885RARA 21/4885 |
| US-12357613-B2 | Inhibitor for retinochoroidal disorders | ALDH1A2, MMP1, RBP1 | RARG 14/4885RARB 11/4885RARA 21/4885 |
| US-20240000768-A1 | METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH SULFATASE DEFICIENCIES | GAA, GBA1, STS | RARG 40/4885RARB 35/4885RARA 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.